Vismodegib: a review.

Abstract

In January 2012, vismodegib (Erivedge, manufactured by Genentech) became the first selective inhibitor of the Hedgehog signaling pathway to be approved by the US Food and Drug Administration for the treatment of locally advanced and metastatic basal cell carcinoma. The drug selectively binds to Smoothened, a 7-helix transmembrane receptor, thereby inhibiting activation of transcription factors of the glioma-associated oncogene family and suppressing tumor proliferation and growth. Studies published to date have assessed the efficacy of vismodegib according to clinical and radiologic outcomes but little information is available on the molecular mechanisms underpinning the proven clinical efficacy of the drug. This review will cover recent data on the Hedgehog signaling pathway and data from clinical trials with vismodegib in the treatment of basal cell carcinoma, and will consider its use in other types of tumor.

• Authors: V Ruiz-Salas, M Alegre, A López-Ferrer, J R Garcés
• Journal: Actas dermo-sifiliograficas (Actas Dermosifiliogr) Vol. 105 Issue 8 Pg. 744-51 (Oct 2014) ISSN: 1578-2190 [Electronic] Spain
• PMID: 24359667 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2013 Elsevier España, S.L.U. y AEDV. All rights reserved.

Chemical References

• Anilides
• Hedgehog Proteins
• HhAntag691
• Pyridines

Topics

• Anilides (pharmacology, therapeutic use)
• Carcinoma, Basal Cell (drug therapy)
• Clinical Trials as Topic
• Hedgehog Proteins (drug effects, physiology)
• Humans
• Pyridines (pharmacology, therapeutic use)
• Signal Transduction (drug effects)
• Skin Neoplasms (drug therapy)